The cytokine network in acute myeloid leukemia
Acute myeloid leukemia (AML) is a highly heterogeneous malignancy of the blood and bone marrow, characterized by clonal expansion of myeloid stem and progenitor cells and rapid disease progression. Chemotherapy has been the first-line treatment for AML for more than 30 years. Application of recent h...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1000996/full |
| _version_ | 1828172702230249472 |
|---|---|
| author | Michela Luciano Michela Luciano Peter W. Krenn Peter W. Krenn Jutta Horejs-Hoeck Jutta Horejs-Hoeck |
| author_facet | Michela Luciano Michela Luciano Peter W. Krenn Peter W. Krenn Jutta Horejs-Hoeck Jutta Horejs-Hoeck |
| author_sort | Michela Luciano |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is a highly heterogeneous malignancy of the blood and bone marrow, characterized by clonal expansion of myeloid stem and progenitor cells and rapid disease progression. Chemotherapy has been the first-line treatment for AML for more than 30 years. Application of recent high-throughput next-generation sequencing technologies has revealed significant molecular heterogeneity to AML, which in turn has motivated efforts to develop new, targeted therapies. However, due to the high complexity of this disease, including multiple driver mutations and the coexistence of multiple competing tumorigenic clones, the successful incorporation of these new agents into clinical practice remains challenging. These continuing difficulties call for the identification of innovative therapeutic approaches that are effective for a larger cohort of AML patients. Recent studies suggest that chronic immune stimulation and aberrant cytokine signaling act as triggers for AML initiation and progression, facets of the disease which might be exploited as promising targets in AML treatment. However, despite the greater appreciation of cytokine profiles in AML, the exact functions of cytokines in AML pathogenesis are not fully understood. Therefore, unravelling the molecular basis of the complex cytokine networks in AML is a prerequisite to develop new therapeutic alternatives based on targeting cytokines and their receptors. |
| first_indexed | 2024-04-12T03:45:07Z |
| format | Article |
| id | doaj.art-599a51f96cc143e5b44fb205ab2200d9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T03:45:07Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-599a51f96cc143e5b44fb205ab2200d92022-12-22T03:49:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.10009961000996The cytokine network in acute myeloid leukemiaMichela Luciano0Michela Luciano1Peter W. Krenn2Peter W. Krenn3Jutta Horejs-Hoeck4Jutta Horejs-Hoeck5Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, AustriaCancer Cluster Salzburg, Salzburg, AustriaDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, AustriaCancer Cluster Salzburg, Salzburg, AustriaDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, AustriaCancer Cluster Salzburg, Salzburg, AustriaAcute myeloid leukemia (AML) is a highly heterogeneous malignancy of the blood and bone marrow, characterized by clonal expansion of myeloid stem and progenitor cells and rapid disease progression. Chemotherapy has been the first-line treatment for AML for more than 30 years. Application of recent high-throughput next-generation sequencing technologies has revealed significant molecular heterogeneity to AML, which in turn has motivated efforts to develop new, targeted therapies. However, due to the high complexity of this disease, including multiple driver mutations and the coexistence of multiple competing tumorigenic clones, the successful incorporation of these new agents into clinical practice remains challenging. These continuing difficulties call for the identification of innovative therapeutic approaches that are effective for a larger cohort of AML patients. Recent studies suggest that chronic immune stimulation and aberrant cytokine signaling act as triggers for AML initiation and progression, facets of the disease which might be exploited as promising targets in AML treatment. However, despite the greater appreciation of cytokine profiles in AML, the exact functions of cytokines in AML pathogenesis are not fully understood. Therefore, unravelling the molecular basis of the complex cytokine networks in AML is a prerequisite to develop new therapeutic alternatives based on targeting cytokines and their receptors.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1000996/fullacute myeloid leukemiacytokine signalinginflammationtumor microenvironmentcytokine inhibitors |
| spellingShingle | Michela Luciano Michela Luciano Peter W. Krenn Peter W. Krenn Jutta Horejs-Hoeck Jutta Horejs-Hoeck The cytokine network in acute myeloid leukemia Frontiers in Immunology acute myeloid leukemia cytokine signaling inflammation tumor microenvironment cytokine inhibitors |
| title | The cytokine network in acute myeloid leukemia |
| title_full | The cytokine network in acute myeloid leukemia |
| title_fullStr | The cytokine network in acute myeloid leukemia |
| title_full_unstemmed | The cytokine network in acute myeloid leukemia |
| title_short | The cytokine network in acute myeloid leukemia |
| title_sort | cytokine network in acute myeloid leukemia |
| topic | acute myeloid leukemia cytokine signaling inflammation tumor microenvironment cytokine inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1000996/full |
| work_keys_str_mv | AT michelaluciano thecytokinenetworkinacutemyeloidleukemia AT michelaluciano thecytokinenetworkinacutemyeloidleukemia AT peterwkrenn thecytokinenetworkinacutemyeloidleukemia AT peterwkrenn thecytokinenetworkinacutemyeloidleukemia AT juttahorejshoeck thecytokinenetworkinacutemyeloidleukemia AT juttahorejshoeck thecytokinenetworkinacutemyeloidleukemia AT michelaluciano cytokinenetworkinacutemyeloidleukemia AT michelaluciano cytokinenetworkinacutemyeloidleukemia AT peterwkrenn cytokinenetworkinacutemyeloidleukemia AT peterwkrenn cytokinenetworkinacutemyeloidleukemia AT juttahorejshoeck cytokinenetworkinacutemyeloidleukemia AT juttahorejshoeck cytokinenetworkinacutemyeloidleukemia |